tirzepatide presentation PDB-101: Diabetes Mellitus: Diabetes Mellitus: undefined: The Science Behind Tirzepatide: GLP-1

D., Seal, D., & Emanuel, F

Experts said the recommendations could widen access as well as driving down cost

Its authors advise plans to pair coverage with lifestyle management programs rather than covering the drug in isolation, to avoid arbitrary duration limits in favor of targeted prior authorization, and to explore subscription-style and value-based payment arrangements

One study using the GLP-1 receptor agonist liraglutide found that it reduced alcohol consumption in rats that had developed a preference for alcohol

Each pre-filled pen delivers a pre-measured 0.25 mg dose and is designed for subcutaneous (under the skin) self-injection